Abstract:Enterovirus 71 (EV-A71) is a major cause of hand, foot, and mouth disease (HFMD). Infection with EV-A71 is more often associated with neurological complications in children and is responsible for the majority of fatalities, but currently there is no approved antiviral therapy for treatment. Here, we identified auraptene, formononetin, and yangonin as effective inhibitors of EV-A71 infection in the low-micromolar range from screening of a natural product library. Among them, formononetin and yangonin selectively inhibited EV-A71 while auraptene could inhibit viruses within the enterovirus species A. Time of addition studies showed that all the three inhibitors inhibit both attachment and postattachment step of entry. We found mutations conferring the resistance to these inhibitors in the VP1 and VP4 capsid proteins and confirmed the target residues using a reverse genetic approach. Interestingly, auraptene- and formononetin-resistant viruses exhibit cross-resistance to other inhibitors while yangonin-resistant virus still remains susceptible to auraptene and formononetin. Moreover, auraptene and formononetin, but not yangonin protected EV-A71 against thermal inactivation, indicating a direct stabilizing effect of both compounds on virion capsid conformation. Finally, neither biochanin A (an analog of formononetin) nor DL-Kavain (an analog of yangonin) exhibited anti-EV-A71 activity, suggesting the structural elements required for anti-EV-A71 activity. Taken together, these compounds could become potential lead compounds for anti-EV-A71 drug development and also serve as tool compounds for studying virus entry.

More-powerful virus inhibitors from structure-based analysis of HEV71 capsid-binding molecules

A Sensor-Adaptor Mechanism for Enterovirus Uncoating from Structures of EV71

New Potent EV-A71 Antivirals Targeting Capsid.

Structure Elucidation of Coxsackievirus A16 in Complex with GPP3 Informs a Systematic Review of Highly Potent Capsid Binders to Enteroviruses.

The Efficacy of Viral Capsid Inhibitors in Human Enterovirus Infection and Associated Diseases.

Characterization of Three Small Molecule Inhibitors of Enterovirus 71 Identified from Screening of a Library of Natural Products

Optimize the interactions at S4 with efficient inhibitors targeting 3C proteinase from enterovirus 71

Identification of a novel binding inhibitor that blocks the interaction between hSCARB2 and VP1 of enterovirus 71

Discovery of Potent EV71 Capsid Inhibitors for Treatment of HFMD

Design, Synthesis, and Evaluation of Novel Enterovirus 71 Inhibitors As Therapeutic Drug Leads for the Treatment of Human Hand, Foot, and Mouth Disease.

Structure-Based Lead Optimization of Enterovirus D68 2A Protease Inhibitors

Identification of Dibucaine Derivatives As Novel Potent Enterovirus 2C Helicase Inhibitors: in Vitro, in Vivo, and Combination Therapy Study

Structure-Based in Silico Screening Identifies a Potent Ebolavirus Inhibitor from a Traditional Chinese Medicine Library

Structure of the Enterovirus 71 3C Protease in Complex with NK-1.8k and Indications for the Development of Antienterovirus Protease Inhibitor

Discovery of Potent and Broad-Spectrum Pyrazolopyridine-Containing Antivirals against Enteroviruses D68, A71, and Coxsackievirus B3 by Targeting the Viral 2C Protein

Design, Synthesis, and Evaluation of Novel Enterovirus 71 Inhibitors as Therapeutic Drug Leads for the Treatment of Human Hand, Foot and Mouth Disease (HFMD).

A Novel Pharmacophore Model Derived from a Class of Capsid Protein Enterovirus 71 Inhibitors

Human enterovirus 71 protein interaction network prompts antiviral drug repositioning

Fragment-wise Design of Inhibitors to 3C Proteinase from Enterovirus 71

IRES-targeting small molecule inhibits enterovirus 71 replication via allosteric stabilization of a ternary complex

Structure-based Discovery of Antiviral Inhibitors Targeting the E Dimer Interface of Japanese Encephalitis Virus.